COVID-19-associated mucormycosis and treatments

Subramaniyan, Vetriselvan; Fuloria, Shivkanya; Darnal, Hari Kumar; Meenakshi, Dhanalekshmi Unnikrishnan; Sekar, Mahendran; Rusli Nordin; Chakravarthi, Srikumar; Sathasivam, Kathiresan V.; Khan, Shah Alam; Wu, Yuan Seng; Kumari, Usha; Sudhakar, Kalvatala; Malviya, Rishabha; Sharma, Vipin Kumar; Fuloria, Neeraj Kumar; (UniKL RCMP)

DSpace Home
→
1. Research Paper
→
Journal Articles
→
View Item

dc.contributor.author	Subramaniyan, Vetriselvan
dc.contributor.author	Fuloria, Shivkanya
dc.contributor.author	Darnal, Hari Kumar
dc.contributor.author	Meenakshi, Dhanalekshmi Unnikrishnan
dc.contributor.author	Sekar, Mahendran
dc.contributor.author	Rusli Nordin
dc.contributor.author	Chakravarthi, Srikumar
dc.contributor.author	Sathasivam, Kathiresan V.
dc.contributor.author	Khan, Shah Alam
dc.contributor.author	Wu, Yuan Seng
dc.contributor.author	Kumari, Usha
dc.contributor.author	Sudhakar, Kalvatala
dc.contributor.author	Malviya, Rishabha
dc.contributor.author	Sharma, Vipin Kumar
dc.contributor.author	Fuloria, Neeraj Kumar
dc.contributor.author	(UniKL RCMP)
dc.date.accessioned	2022-11-21T02:43:25Z
dc.date.available	2022-11-21T02:43:25Z
dc.date.issued	2021-09
dc.identifier.citation	Fuloria, S., Fuloria, N., Subramaniyan, V., Darnal, H., Meenakshi, D., Sekar, M., Rusli Nordin, Chakravarthi, S., Sathasivam, K., Khan, S., Wu, Y., Kumari, U., Sudhakar, K., Malviya, R., & Sharma, V. (2021). COVID-19-associated mucormycosis and treatments. Asian Pacific Journal of Tropical Medicine, 14(9), 401. https://doi.org/10.4103/1995-7645.326253	en_US
dc.identifier.issn	19957645
dc.identifier.uri	https://www.apjtm.org/article.asp?issn=1995-7645;year=2021;volume=14;issue=9;spage=401;epage=409;aulast=Subramaniyan;type=0
dc.identifier.uri	http://hdl.handle.net/123456789/26307
dc.description.abstract	In the current pandemic, COVID-19 patients with predisposing factors are at an increased risk of mucormycosis, an uncommon angioinvasive infection that is caused by fungi with Mucor genus which is mainly found in plants and soil. Mucormycosis development in COVID-19 patient is related to various factors, such as diabetes, immunocompromise and neutropenia. Excessive use of glucocorticoids for the treatment of critically ill COVID-19 patients also leads to opportunistic infections, such as pulmonary aspergillosis. COVID-19 patients with mucormycosis have a very high mortality rate. This review describes the pathogenesis and various treatment approaches for mucormycosis in COVID-19 patients, including medicinal plants, conventional therapies, adjunct and combination therapies	en_US
dc.language.iso	en	en_US
dc.publisher	Wolters Kluwer Medknow Publications	en_US
dc.subject	COVID-19	en_US
dc.subject	Immunosuppression	en_US
dc.subject	Mucormycosis	en_US
dc.subject	Pathogenesis	en_US
dc.subject	Treatment	en_US
dc.title	COVID-19-associated mucormycosis and treatments	en_US
dc.type	Other	en_US